Drug makers hold negative view on drug re-categorization

Published: 2011-08-30 07:00:00

Updated: 2011-08-30 07:00:00

Pharmaceutical companies expressed a negative view toward the idea of re-categorizing medicines as part of measures to reduce customers' inconvenience in buying drugs and strengthen monitoring of drug use.

The reaction came after the Korea Food and Drug Association (KFDA) Monday announced it h...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK